Merck touts updated 21-valent pneumococcal data weeks ahead of FDA decision: Corrected

Mer­ck bol­stered its pneu­mo­coc­cal vac­cine da­ta on Mon­day, as the com­pa­ny looks to one-up Pfiz­er’s Pre­vnar 20 shot.

Mer­ck said that its new con­ju­gate vac­cine, called V116, proved non­in­fe­ri­or to its much old­er Pneu­movax 23 vac­cine for all 12 strains com­mon to both vac­cines. Pneu­movax 23 is a 23-va­lent poly­sac­cha­ride vac­cine ap­proved in 1982. More mod­ern  “con­ju­gat­ed” vac­cines are de­signed to work bet­ter in younger chil­dren and po­ten­tial­ly last longer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.